美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

艾格里房產

71.75

+0.49000.69%

盤後：71.750.00000.00%19:39 EST

成交量：97.21萬

成交額：6,963.35萬

市值：82.47億

市盈率：41.91

高：72.00

開：71.38

低：71.24

收：71.26

52周最高：79.65

52周最低：67.58

股本：1.15億

流通股本：1.08億

量比：0.74

換手率：0.90%

股息：3.05

股息率：4.26%

每股收益(TTM):1.71

每股收益(LYR):1.79

淨資產收益率：3.48%

總資產收益率：2.33%

市淨率：1.45

市盈率(LYR):40.02

資料載入中...

總覽公司新聞資訊公告

【券商聚焦】交銀國際上調康寧傑瑞製藥(09966)評級至買入看好其ADC產品矩陣的巨大全球市場潛力

新股前瞻|佈局TCE腫瘤療法千億藍海，時邁藥業能否博得市場青睞？

牽手尋合作，科倫博泰能否破解業績困局？

超13億美元！科倫博泰 ADC 出海選擇管線互換模式

国际金融报

ADC藥物與PD-1/VEGF雙抗聯用再添案例科倫博泰與Crescent達成雙向授權協議

每日经济新闻

港股異動 | 百奧賽圖-B(02315)漲超3% 授權IDEAYA雙抗ADC項目IDE034獲FDA IND批准

ADC與PD-1紅海之外，寶濟藥業如何找到生物醫藥的「第二增長曲線」？

新聞稿：Akari Therapeutics 提供公司更新，重點介紹其 ADC 載荷創新，預計將在新 CEO 角落中驅動價值

復宏漢霖PD-L1 ADC II期結果讀出；*ST蘇吳進入退市整理期｜醫藥早參

每日经济新闻

Macrogenics, Inc.盤中異動股價大跌5.23%

興證國際：首予映恩生物-B(09606)「增持」評級公司立足創新持續引領下一代ADC研發浪潮

港股異動 | 中國生物製藥(01177)漲超4% 旗下正大晴天自研HER2雙抗ADC新輔助治療乳腺癌取得重要突破

科倫博泰 ADC 聯合 K 藥闖過一線肺癌 III 期，中國患者將迎新方案？

港股異動 | 和鉑醫藥-B(02142)漲近5% 與阿斯利康進一步拓展合作範圍開發ADC及T細胞銜接器療法

和鉑醫藥-B與 AstraZeneca修訂合作協議合作範圍進一步擴展

百利天恆：全球首個EGFR x HER3雙抗ADC藥物iza-bren上市申請成功獲CDE受理

智通港股解盤 | 券商收購合併再起傳聞引發地產走強

開發下一代 ADC，新鋭孖展1.2億美元，默沙東支持

中國生物製藥(01177)：LM-350「CDH17 ADC」臨牀試驗申請獲NMPA批准

歷史性突破！「中國智造」ADC新藥全球首個取得食管癌III期臨牀研究成功

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ADC/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房產","latestPrice":71.75,"timestamp":1765573200000,"preClose":71.26,"halted":0,"volume":972110,"hourTrading":{"tag":"盘后","latestPrice":71.75,"preClose":71.75,"latestTime":"19:39 EST","volume":84227,"amount":6043288.593,"timestamp":1765586379736},"delay":0,"floatShares":108366822,"shares":114934390,"eps":1.712089,"marketStatus":"休市中","change":0.49,"latestTime":"12-12 16:00:00 EST","open":71.38,"high":72,"low":71.24,"amount":69633464.1586,"amplitude":0.010665,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.712089,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":71.26,"dividendRate":0.042564,"preHourTrading":{"tag":"盘前","latestPrice":71.37,"preClose":71.26,"latestTime":"08:00 EST","volume":51,"amount":3638.330106,"timestamp":1765544402863},"postHourTrading":{"tag":"盘后","latestPrice":71.75,"preClose":71.75,"latestTime":"19:39 EST","volume":84227,"amount":6043288.593,"timestamp":1765586379736},"volumeRatio":0.7407340522359658,"impliedVol":0.187,"impliedVolPercentile":0.12},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","floatShares":108366822,"roa":"2.33%","roe":"3.48%","lyrEps":1.793039,"volumeRatio":0.7407340522359658,"shares":114934390,"dividePrice":3.054,"high":72,"amplitude":0.010665,"preClose":71.26,"low":71.24,"week52Low":67.58,"pbRate":"1.45","psRate":"11.98","week52High":79.65,"institutionHeld":0.9801,"latestPrice":71.75,"eps":1.712089,"divideRate":0.042564,"volume":972110,"delay":0,"ttmEps":1.712089,"open":71.38,"prevYearClose":70.45,"prevWeekClose":73.9,"prevMonthClose":75.22,"prevQuarterClose":71.04,"fiveDayClose":73.9,"twentyDayClose":73.7,"sixtyDayClose":71.53,"dividendPayoutRate":1.673137059483926,"dividendFrequency":"M","dividendGrowthYears":9,"dividendGrowthRate":0.027749229188078095,"fiveYearAvgDividendRate":0.040404410811749565},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC\",params:#limit:5,,,undefined,":[{"date":"2025-12-31","symbol":"ADC","amount":0.262,"announcedDate":"2025-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-31","defaultRemindTime":1767191400000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-15","payableDate":"2025-12-31","currency":"USD","dateTimestamp":1767157200000,"payDate":"2026-01-15"},{"date":"2025-11-28","symbol":"ADC","amount":0.262,"announcedDate":"2025-11-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-28","defaultRemindTime":1764340200000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-12","payableDate":"2025-11-28","currency":"USD","dateTimestamp":1764306000000,"payDate":"2025-12-12"},{"date":"2025-10-31","symbol":"ADC","amount":0.262,"announcedDate":"2025-10-14","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-10-31","defaultRemindTime":1761917400000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-14","payableDate":"2025-10-31","currency":"USD","dateTimestamp":1761883200000,"payDate":"2025-11-14"},{"date":"2025-10-21","symbol":"ADC","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/09","expectedEps":1.05,"defaultRemindTime":1761076800000,"name":null,"time":"盤後","dateTimestamp":1761019200000,"actualEps":1.03},{"date":"2025-09-30","symbol":"ADC","amount":0.256,"announcedDate":"2025-09-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-30","defaultRemindTime":1759239000000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-14","payableDate":"2025-09-30","currency":"USD","dateTimestamp":1759204800000,"payDate":"2025-10-14"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC\",market:\"US\",,,undefined,":[{"executeDate":"2015-12-18","recordDate":"2015-12-22","paymentDate":"2016-01-05","value":0.465,"currency":"USD"},{"executeDate":"2016-03-29","recordDate":"2016-03-31","paymentDate":"2016-04-15","value":0.465,"currency":"USD"},{"executeDate":"2016-06-28","recordDate":"2016-06-30","paymentDate":"2016-07-15","value":0.48,"currency":"USD"},{"executeDate":"2016-09-28","recordDate":"2016-09-30","paymentDate":"2016-10-14","value":0.48,"currency":"USD"},{"executeDate":"2016-12-21","recordDate":"2016-12-23","paymentDate":"2017-01-03","value":0.495,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.381,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.381,"analysts":21,"updateTime":1752123600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ADC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ADC","date":"2025-12-12","current":41.907868,"percent":0.551303,"low":31.539495,"twenty":37.639342,"median":41.619337,"eighty":44.656944,"high":53.261716,"avg":41.37002,"sd":4.481562,"marketCap":8176400191},"quantilePoints":[{"date":"2020-12-18","current":39.344831,"twenty":31.975443,"median":38.676992,"eighty":43.037844,"marketCap":3553821844},{"date":"2020-12-24","current":39.762935,"twenty":31.975443,"median":38.782235,"eighty":43.037844,"marketCap":3591587102},{"date":"2020-12-31","current":40.937316,"twenty":31.975443,"median":38.892751,"eighty":43.037844,"marketCap":3697663047},{"date":"2021-01-08","current":45.450661,"twenty":31.975443,"median":39.008592,"eighty":43.047885,"marketCap":4105330986},{"date":"2021-01-15","current":44.653159,"twenty":31.975443,"median":39.245492,"eighty":43.22631,"marketCap":4033296550},{"date":"2021-01-22","current":45.359718,"twenty":31.975443,"median":39.341757,"eighty":43.313411,"marketCap":4097116533},{"date":"2021-01-29","current":44.212433,"twenty":31.975443,"median":39.41667,"eighty":43.4163,"marketCap":3993488046},{"date":"2021-02-05","current":46.262155,"twenty":31.975443,"median":39.41667,"eighty":43.554978,"marketCap":4178629185},{"date":"2021-02-12","current":45.520618,"twenty":31.975443,"median":39.41667,"eighty":43.618647,"marketCap":4111649797},{"date":"2021-02-19","current":43.859591,"twenty":31.975443,"median":39.41667,"eighty":43.642628,"marketCap":4007933303},{"date":"2021-02-26","current":44.718497,"twenty":31.977009,"median":39.430911,"eighty":43.756513,"marketCap":4086420942},{"date":"2021-03-05","current":44.656157,"twenty":31.975443,"median":39.41667,"eighty":43.796506,"marketCap":4080724259},{"date":"2021-03-12","current":46.594043,"twenty":31.975443,"median":39.41667,"eighty":43.856021,"marketCap":4257810284},{"date":"2021-03-19","current":46.240217,"twenty":31.975443,"median":39.41667,"eighty":43.889974,"marketCap":4225477299},{"date":"2021-03-26","current":46.69811,"twenty":31.977009,"median":39.430911,"eighty":43.995818,"marketCap":4267319985},{"date":"2021-04-01","current":47.239256,"twenty":31.977009,"median":39.430911,"eighty":44.083322,"marketCap":4316770432},{"date":"2021-04-09","current":47.1005,"twenty":31.975443,"median":39.41667,"eighty":44.146464,"marketCap":4304090831},{"date":"2021-04-16","current":47.627771,"twenty":31.975443,"median":39.41667,"eighty":44.201737,"marketCap":4352273317},{"date":"2021-04-23","current":49.334461,"twenty":31.975443,"median":39.41667,"eighty":44.216631,"marketCap":4508232419},{"date":"2021-04-30","current":48.814129,"twenty":31.975443,"median":39.41667,"eighty":44.274005,"marketCap":4460683913},{"date":"2021-05-07","current":44.881383,"twenty":31.975443,"median":39.41667,"eighty":44.314742,"marketCap":4499986938},{"date":"2021-05-14","current":44.377456,"twenty":31.975443,"median":39.41667,"eighty":44.249425,"marketCap":4449461218},{"date":"2021-05-21","current":44.026621,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4414285084},{"date":"2021-05-28","current":44.830352,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4494870410},{"date":"2021-06-04","current":45.665977,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4578653566},{"date":"2021-06-11","current":45.646841,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4576734868},{"date":"2021-06-18","current":47.246871,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4737160278},{"date":"2021-06-25","current":48.748389,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4887708512},{"date":"2021-07-02","current":48.211648,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4833892628},{"date":"2021-07-09","current":49.210395,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4934031046},{"date":"2021-07-16","current":49.93058,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":5006239701},{"date":"2021-07-23","current":50.956505,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":5109102975},{"date":"2021-07-30","current":53.056971,"twenty":31.977009,"median":39.430911,"eighty":44.230599,"marketCap":5165308396},{"date":"2021-08-06","current":52.598062,"twenty":31.977009,"median":39.430911,"eighty":44.296692,"marketCap":5120631744},{"date":"2021-08-13","current":52.520401,"twenty":31.977009,"median":39.430911,"eighty":44.412506,"marketCap":5113071079},{"date":"2021-08-20","current":52.718085,"twenty":31.977009,"median":39.430911,"eighty":44.625208,"marketCap":5132316407},{"date":"2021-08-27","current":52.209754,"twenty":31.977009,"median":39.430911,"eighty":44.658936,"marketCap":5082828422},{"date":"2021-09-03","current":52.675724,"twenty":31.977009,"median":39.430911,"eighty":44.712504,"marketCap":5128192408},{"date":"2021-09-10","current":49.555141,"twenty":31.977009,"median":39.430911,"eighty":44.74795,"marketCap":4824391169},{"date":"2021-09-17","current":50.119952,"twenty":31.977009,"median":39.430911,"eighty":44.835833,"marketCap":4879377818},{"date":"2021-09-24","current":47.775985,"twenty":31.977009,"median":39.430911,"eighty":44.888065,"marketCap":4651183223},{"date":"2021-10-01","current":47.352376,"twenty":31.977009,"median":39.430911,"eighty":44.941549,"marketCap":4609943235},{"date":"2021-10-08","current":47.670083,"twenty":31.977009,"median":39.430911,"eighty":44.9864,"marketCap":4640873226},{"date":"2021-10-15","current":49.02563,"twenty":31.977009,"median":39.430911,"eighty":45.094688,"marketCap":4772841185},{"date":"2021-10-22","current":49.5269,"twenty":31.977009,"median":39.430911,"eighty":45.190701,"marketCap":4821641836},{"date":"2021-10-29","current":50.169373,"twenty":32.013133,"median":39.571166,"eighty":45.28245,"marketCap":4884189150},{"date":"2021-11-05","current":43.773853,"twenty":32.013133,"median":39.651928,"eighty":45.28245,"marketCap":4934976633},{"date":"2021-11-12","current":43.137928,"twenty":32.029424,"median":39.72736,"eighty":45.28245,"marketCap":4863283742},{"date":"2021-11-19","current":43.008274,"twenty":32.198132,"median":39.802558,"eighty":45.28245,"marketCap":4848666745},{"date":"2021-11-26","current":42.662528,"twenty":32.27459,"median":39.842867,"eighty":45.28245,"marketCap":4809688086},{"date":"2021-12-03","current":42.508177,"twenty":32.348817,"median":39.911012,"eighty":45.28245,"marketCap":4792286899},{"date":"2021-12-10","current":42.891493,"twenty":32.447032,"median":39.953188,"eighty":45.28245,"marketCap":4835501148},{"date":"2021-12-17","current":45.380751,"twenty":32.521786,"median":39.996581,"eighty":45.380751,"marketCap":5116135105},{"date":"2021-12-23","current":46.352906,"twenty":32.588031,"median":40.079057,"eighty":45.406143,"marketCap":5225733953},{"date":"2021-12-31","current":48.175698,"twenty":32.64443,"median":40.10618,"eighty":45.47788,"marketCap":5431231792},{"date":"2022-01-07","current":46.703962,"twenty":32.651599,"median":40.164071,"eighty":45.565296,"marketCap":5265311314},{"date":"2022-01-14","current":46.015352,"twenty":32.70478,"median":40.208708,"eighty":45.667046,"marketCap":5187678797},{"date":"2022-01-21","current":43.267663,"twenty":32.731462,"median":40.224323,"eighty":45.667046,"marketCap":4877909831},{"date":"2022-01-28","current":43.821252,"twenty":32.743358,"median":40.249944,"eighty":45.667046,"marketCap":4940320287},{"date":"2022-02-04","current":42.666817,"twenty":32.769192,"median":40.314701,"eighty":45.667046,"marketCap":4810171655},{"date":"2022-02-11","current":42.565551,"twenty":32.769192,"median":40.347561,"eighty":45.667046,"marketCap":4798755108},{"date":"2022-02-18","current":42.943612,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4841376882},{"date":"2022-02-25","current":37.784604,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4620036905},{"date":"2022-03-04","current":38.267307,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4679058463},{"date":"2022-03-11","current":37.29027,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4559593141},{"date":"2022-03-18","current":37.24956,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4554615419},{"date":"2022-03-25","current":38.110019,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4659826391},{"date":"2022-04-01","current":39.298046,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4805089927},{"date":"2022-04-08","current":39.763938,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4862056020},{"date":"2022-04-14","current":40.742313,"twenty":32.769192,"median":40.404479,"eighty":45.667046,"marketCap":4981684815},{"date":"2022-04-22","current":42.01187,"twenty":32.769192,"median":40.455317,"eighty":45.667046,"marketCap":5136917418},{"date":"2022-04-29","current":39.554287,"twenty":32.79826,"median":40.479695,"eighty":45.667046,"marketCap":4836421278},{"date":"2022-05-06","current":39.499614,"twenty":32.904642,"median":40.479695,"eighty":45.667046,"marketCap":5066773466},{"date":"2022-05-13","current":39.967203,"twenty":32.996397,"median":40.479695,"eighty":45.667046,"marketCap":5126753027},{"date":"2022-05-20","current":39.90291,"twenty":33.05702,"median":40.479695,"eighty":45.667046,"marketCap":5118505838},{"date":"2022-05-27","current":40.353768,"twenty":33.088236,"median":40.495181,"eighty":45.667046,"marketCap":5176339242},{"date":"2022-06-03","current":40.599257,"twenty":33.156377,"median":40.53176,"eighty":45.667046,"marketCap":5207829139},{"date":"2022-06-10","current":41.119461,"twenty":33.227354,"median":40.613635,"eighty":45.667046,"marketCap":5274557730},{"date":"2022-06-17","current":40.213488,"twenty":33.270165,"median":40.613635,"eighty":45.667046,"marketCap":5158345016},{"date":"2022-06-24","current":43.32302,"twenty":33.260026,"median":40.659236,"eighty":45.668114,"marketCap":5557217043},{"date":"2022-07-01","current":42.978166,"twenty":33.330747,"median":40.684242,"eighty":45.668114,"marketCap":5512981235},{"date":"2022-07-08","current":42.872956,"twenty":33.466784,"median":40.715658,"eighty":45.668114,"marketCap":5499485565},{"date":"2022-07-15","current":43.708789,"twenty":33.59929,"median":40.742313,"eighty":45.668114,"marketCap":5606701167},{"date":"2022-07-22","current":44.556311,"twenty":33.59929,"median":40.778643,"eighty":45.668114,"marketCap":5715416287},{"date":"2022-07-29","current":46.520226,"twenty":33.675236,"median":40.820493,"eighty":45.678143,"marketCap":5967335462},{"date":"2022-08-05","current":43.100932,"twenty":33.675236,"median":40.862996,"eighty":45.68777,"marketCap":6116022220},{"date":"2022-08-12","current":44.318758,"twenty":33.675236,"median":40.912721,"eighty":45.68777,"marketCap":6288831702},{"date":"2022-08-19","current":44.509569,"twenty":33.675236,"median":40.969109,"eighty":45.68777,"marketCap":6315907842},{"date":"2022-08-26","current":43.241234,"twenty":33.675236,"median":41.010201,"eighty":45.68777,"marketCap":6135931147},{"date":"2022-09-02","current":41.585665,"twenty":33.675236,"median":41.060268,"eighty":45.68777,"marketCap":5901005814},{"date":"2022-09-09","current":41.956063,"twenty":33.675236,"median":41.092655,"eighty":45.68777,"marketCap":5953565380},{"date":"2022-09-16","current":40.805583,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5790312183},{"date":"2022-09-23","current":39.935707,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5666876838},{"date":"2022-09-30","current":37.927001,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5381841428},{"date":"2022-10-07","current":36.428553,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5169211706},{"date":"2022-10-14","current":35.631626,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5056127734},{"date":"2022-10-21","current":36.636203,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5198677248},{"date":"2022-10-28","current":38.359137,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5443161610},{"date":"2022-11-04","current":41.724424,"twenty":33.675236,"median":41.119461,"eighty":45.68777,"marketCap":6035896875},{"date":"2022-11-11","current":42.347632,"twenty":33.675236,"median":41.160749,"eighty":45.68777,"marketCap":6126050848},{"date":"2022-11-18","current":42.756995,"twenty":33.675236,"median":41.197005,"eighty":45.68777,"marketCap":6185269635},{"date":"2022-11-25","current":43.056379,"twenty":33.675236,"median":41.218321,"eighty":45.68777,"marketCap":6228578896},{"date":"2022-12-02","current":43.196907,"twenty":33.675236,"median":41.257018,"eighty":45.68777,"marketCap":6248907733},{"date":"2022-12-09","current":43.795676,"twenty":33.675236,"median":41.35326,"eighty":45.68777,"marketCap":6335526256},{"date":"2022-12-16","current":43.172467,"twenty":33.675236,"median":41.423201,"eighty":45.68777,"marketCap":6245372283},{"date":"2022-12-23","current":43.685698,"twenty":33.675236,"median":41.463369,"eighty":45.68777,"marketCap":6319616732},{"date":"2022-12-30","current":43.337434,"twenty":33.675236,"median":41.483593,"eighty":45.68777,"marketCap":6269236570},{"date":"2023-01-06","current":43.245786,"twenty":34.167053,"median":41.539601,"eighty":45.68777,"marketCap":6255978633},{"date":"2023-01-13","current":45.714181,"twenty":34.992765,"median":41.587683,"eighty":45.704396,"marketCap":6613059075},{"date":"2023-01-20","current":45.402576,"twenty":35.880519,"median":41.605991,"eighty":45.714503,"marketCap":6567982088},{"date":"2023-01-27","current":45.378137,"twenty":36.169649,"median":41.646285,"eighty":45.714503,"marketCap":6564446638},{"date":"2023-02-03","current":45.255939,"twenty":36.592515,"median":41.674422,"eighty":45.714503,"marketCap":6546769389},{"date":"2023-02-10","current":44.406665,"twenty":36.713651,"median":41.711398,"eighty":45.714503,"marketCap":6423912504},{"date":"2023-02-17","current":44.157808,"twenty":36.89773,"median":41.739833,"eighty":45.714503,"marketCap":6731283715},{"date":"2023-02-24","current":42.410386,"twenty":36.963658,"median":41.754028,"eighty":45.714503,"marketCap":6464912060},{"date":"2023-03-03","current":41.690165,"twenty":37.214665,"median":41.783816,"eighty":45.714503,"marketCap":6355123742},{"date":"2023-03-10","current":39.423241,"twenty":37.286636,"median":41.783816,"eighty":45.714503,"marketCap":6009560514},{"date":"2023-03-17","current":40.355986,"twenty":37.342014,"median":41.783816,"eighty":45.714503,"marketCap":6151745384},{"date":"2023-03-24","current":39.606247,"twenty":37.466803,"median":41.783816,"eighty":45.714503,"marketCap":6037457546},{"date":"2023-03-31","current":40.621801,"twenty":37.536428,"median":41.78137,"eighty":45.714342,"marketCap":6192265465},{"date":"2023-04-06","current":39.692254,"twenty":37.577737,"median":41.783816,"eighty":45.714503,"marketCap":6050568092},{"date":"2023-04-14","current":39.289647,"twenty":37.687654,"median":41.784219,"eighty":45.714663,"marketCap":5989195981},{"date":"2023-04-21","current":39.792905,"twenty":37.872566,"median":41.784621,"eighty":45.714824,"marketCap":6065911119},{"date":"2023-04-28","current":40.118543,"twenty":37.943837,"median":41.797292,"eighty":45.714985,"marketCap":6115550327},{"date":"2023-05-05","current":39.964605,"twenty":38.110019,"median":41.797292,"eighty":45.714985,"marketCap":6092084520},{"date":"2023-05-12","current":39.104119,"twenty":38.249787,"median":41.797292,"eighty":45.714985,"marketCap":6176026400},{"date":"2023-05-19","current":38.898029,"twenty":38.342909,"median":41.797292,"eighty":45.714985,"marketCap":6143476946},{"date":"2023-05-26","current":37.796919,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5969569863},{"date":"2023-06-02","current":37.832249,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5975149770},{"date":"2023-06-09","current":38.668386,"twenty":38.476762,"median":41.797292,"eighty":45.714985,"marketCap":6107207554},{"date":"2023-06-16","current":38.786152,"twenty":38.533217,"median":41.797292,"eighty":45.714985,"marketCap":6125807242},{"date":"2023-06-23","current":38.509402,"twenty":38.553397,"median":41.809962,"eighty":45.718688,"marketCap":6082097976},{"date":"2023-06-30","current":38.55062,"twenty":38.5799,"median":41.81327,"eighty":45.72239,"marketCap":6088607866},{"date":"2023-07-07","current":38.662498,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6106277570},{"date":"2023-07-14","current":38.603615,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6096977726},{"date":"2023-07-21","current":39.357316,"twenty":38.659115,"median":41.81327,"eighty":45.72239,"marketCap":6216015729},{"date":"2023-07-28","current":39.404422,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6223455604},{"date":"2023-08-04","current":38.053978,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6196443469},{"date":"2023-08-11","current":37.511193,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6108060089},{"date":"2023-08-18","current":36.166029,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5889023018},{"date":"2023-08-25","current":36.531819,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5948585730},{"date":"2023-09-01","current":36.472821,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5938978841},{"date":"2023-09-08","current":35.75304,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5821774794},{"date":"2023-09-15","current":35.446248,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5771818971},{"date":"2023-09-22","current":33.711695,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5489376431},{"date":"2023-09-29","current":32.567126,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5303002783},{"date":"2023-10-06","current":32.649724,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5316452427},{"date":"2023-10-13","current":31.806046,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5179073913},{"date":"2023-10-20","current":32.41963,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5278985560},{"date":"2023-10-27","current":33.181375,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5472604212},{"date":"2023-11-03","current":35.377246,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5834769220},{"date":"2023-11-10","current":34.598655,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5706356142},{"date":"2023-11-17","current":35.425908,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5842795038},{"date":"2023-11-24","current":35.170433,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5800659496},{"date":"2023-12-01","current":36.015934,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5940108073},{"date":"2023-12-08","current":36.873602,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6081563104},{"date":"2023-12-15","current":37.7556,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6227031044},{"date":"2023-12-22","current":37.968496,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6262143995},{"date":"2023-12-29","current":38.607184,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":6367482847},{"date":"2024-01-05","current":38.296964,"twenty":38.756995,"median":41.871582,"eighty":45.73451,"marketCap":6316318262},{"date":"2024-01-12","current":38.090151,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":6282208538},{"date":"2024-01-19","current":36.989174,"twenty":38.764196,"median":41.872103,"eighty":45.735522,"marketCap":6100624420},{"date":"2024-01-26","current":36.295741,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":5986256523},{"date":"2024-02-02","current":37.232484,"twenty":38.697827,"median":41.871582,"eighty":45.73451,"marketCap":6140753507},{"date":"2024-02-09","current":35.261674,"twenty":38.661168,"median":41.871582,"eighty":45.73451,"marketCap":5815707904},{"date":"2024-02-16","current":33.847315,"twenty":38.629468,"median":41.871582,"eighty":45.73451,"marketCap":5752655855},{"date":"2024-02-23","current":33.670228,"twenty":38.597685,"median":41.871582,"eighty":45.73451,"marketCap":5722558249},{"date":"2024-03-01","current":32.436519,"twenty":38.556509,"median":41.871061,"eighty":45.733498,"marketCap":5512878257},{"date":"2024-03-08","current":33.758772,"twenty":38.535146,"median":41.871061,"eighty":45.733498,"marketCap":5737607052},{"date":"2024-03-15","current":32.6018,"twenty":38.489062,"median":41.871061,"eighty":45.733498,"marketCap":5540969356},{"date":"2024-03-22","current":33.262927,"twenty":38.456408,"median":41.871061,"eighty":45.733498,"marketCap":5653333754},{"date":"2024-03-28","current":33.457723,"twenty":38.385748,"median":41.784621,"eighty":45.733498,"marketCap":5686441121},{"date":"2024-04-05","current":33.192092,"twenty":38.338315,"median":41.766476,"eighty":45.73451,"marketCap":5641294711},{"date":"2024-04-12","current":33.499043,"twenty":38.271415,"median":41.746116,"eighty":45.73451,"marketCap":5693463896},{"date":"2024-04-19","current":32.99201,"twenty":38.226469,"median":41.73308,"eighty":45.73451,"marketCap":5607289064},{"date":"2024-04-26","current":33.647761,"twenty":38.150217,"median":41.720309,"eighty":45.733498,"marketCap":5827926731},{"date":"2024-05-03","current":33.618779,"twenty":38.090151,"median":41.711398,"eighty":45.733498,"marketCap":5822906984},{"date":"2024-05-10","current":34.482434,"twenty":38.029323,"median":41.69585,"eighty":45.733498,"marketCap":5972495456},{"date":"2024-05-17","current":34.986715,"twenty":37.950247,"median":41.66791,"eighty":45.733498,"marketCap":6059839061},{"date":"2024-05-24","current":34.198413,"twenty":37.871294,"median":41.619337,"eighty":45.733498,"marketCap":5923301932},{"date":"2024-05-31","current":34.928752,"twenty":37.820473,"median":41.602226,"eighty":45.733498,"marketCap":6049799566},{"date":"2024-06-07","current":35.908334,"twenty":37.7418,"median":41.585665,"eighty":45.733498,"marketCap":6219467028},{"date":"2024-06-14","current":35.311311,"twenty":37.642264,"median":41.478607,"eighty":45.73451,"marketCap":6116060232},{"date":"2024-06-21","current":35.485201,"twenty":37.563829,"median":41.447441,"eighty":45.735522,"marketCap":6146178716},{"date":"2024-06-28","current":35.734443,"twenty":37.537078,"median":41.447441,"eighty":45.738558,"marketCap":6189348544},{"date":"2024-07-05","current":35.879352,"twenty":37.482188,"median":41.447441,"eighty":45.738558,"marketCap":6214447281},{"date":"2024-07-12","current":36.957471,"twenty":37.418215,"median":41.439295,"eighty":45.738558,"marketCap":6401181884},{"date":"2024-07-15","current":37.189325,"twenty":37.412399,"median":41.439295,"eighty":45.738558,"marketCap":6441339863},{"date":"2024-08-02","current":37.993919,"twenty":37.339153,"median":41.40142,"eighty":45.707657,"marketCap":7107142493},{"date":"2024-08-09","current":38.417922,"twenty":37.339153,"median":41.351038,"eighty":45.669183,"marketCap":7186456557},{"date":"2024-08-16","current":38.455492,"twenty":37.339153,"median":41.248609,"eighty":45.587895,"marketCap":7193484385},{"date":"2024-08-23","current":38.879496,"twenty":37.339153,"median":41.197005,"eighty":45.51208,"marketCap":7272798449},{"date":"2024-08-30","current":39.104915,"twenty":37.339153,"median":41.152223,"eighty":45.432939,"marketCap":7314965420},{"date":"2024-09-06","current":40.19981,"twenty":37.339153,"median":41.109476,"eighty":45.406991,"marketCap":7519776420},{"date":"2024-09-13","current":40.725789,"twenty":37.339153,"median":41.060268,"eighty":45.379705,"marketCap":7618166018},{"date":"2024-09-20","current":39.786541,"twenty":37.339153,"median":41.020981,"eighty":45.296882,"marketCap":7442470307},{"date":"2024-09-27","current":39.931453,"twenty":37.339153,"median":40.992653,"eighty":45.271719,"marketCap":7469577645},{"date":"2024-10-04","current":40.355457,"twenty":37.339153,"median":40.937316,"eighty":45.211095,"marketCap":7548891709},{"date":"2024-10-11","current":39.3196,"twenty":37.339153,"median":40.894276,"eighty":45.159517,"marketCap":7355124439},{"date":"2024-10-18","current":40.731156,"twenty":37.339153,"median":40.838938,"eighty":45.089028,"marketCap":7619169993},{"date":"2024-10-25","current":42.532506,"twenty":37.339153,"median":40.820493,"eighty":45.046981,"marketCap":8077475775},{"date":"2024-10-31","current":40.816625,"twenty":37.339153,"median":40.816625,"eighty":44.988744,"marketCap":7751607762},{"date":"2024-11-08","current":40.076878,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7611120201},{"date":"2024-11-15","current":41.115788,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7808422584},{"date":"2024-11-22","current":41.948003,"twenty":37.338438,"median":40.773001,"eighty":44.914929,"marketCap":7966471090},{"date":"2024-11-29","current":41.773945,"twenty":37.338438,"median":40.773001,"eighty":44.914324,"marketCap":7933415193},{"date":"2024-12-06","current":40.849261,"twenty":37.338438,"median":40.770318,"eighty":44.892115,"marketCap":7757805742},{"date":"2024-12-13","current":40.055121,"twenty":37.338438,"median":40.736734,"eighty":44.892115,"marketCap":7606988214},{"date":"2024-12-20","current":37.770608,"twenty":37.338438,"median":40.680888,"eighty":44.892115,"marketCap":7173129570},{"date":"2024-12-27","current":38.515795,"twenty":37.338438,"median":40.640959,"eighty":44.892115,"marketCap":7314650128},{"date":"2025-01-03","current":37.933788,"twenty":37.338438,"median":40.614232,"eighty":44.892115,"marketCap":7204119473},{"date":"2025-01-10","current":37.906591,"twenty":37.337724,"median":40.580698,"eighty":44.89414,"marketCap":7198954490},{"date":"2025-01-17","current":39.244663,"twenty":37.333873,"median":40.538993,"eighty":44.89414,"marketCap":7453071695},{"date":"2025-01-24","current":38.87479,"twenty":37.333873,"median":40.501145,"eighty":44.89414,"marketCap":7382827915},{"date":"2025-01-31","current":39.761398,"twenty":37.333873,"median":40.465332,"eighty":44.84311,"marketCap":7551206388},{"date":"2025-02-07","current":39.74508,"twenty":37.333873,"median":40.424995,"eighty":44.718497,"marketCap":7548107398},{"date":"2025-02-14","current":40.634976,"twenty":37.333873,"median":40.403761,"eighty":44.67404,"marketCap":7688015540},{"date":"2025-02-21","current":40.363435,"twenty":37.333873,"median":40.374953,"eighty":44.653159,"marketCap":7636640801},{"date":"2025-02-28","current":41.687197,"twenty":37.333873,"median":40.374953,"eighty":44.559412,"marketCap":7887092651},{"date":"2025-03-07","current":42.394335,"twenty":37.33306,"median":40.37194,"eighty":44.562299,"marketCap":8020881032},{"date":"2025-03-14","current":42.767704,"twenty":37.33306,"median":40.383179,"eighty":44.562299,"marketCap":8091521298},{"date":"2025-03-21","current":43.141073,"twenty":37.417052,"median":40.40791,"eighty":44.562299,"marketCap":8162161563},{"date":"2025-03-28","current":42.993988,"twenty":37.479862,"median":40.452151,"eighty":44.562299,"marketCap":8134333580},{"date":"2025-04-04","current":43.440899,"twenty":37.536428,"median":40.487288,"eighty":44.562299,"marketCap":8218887836},{"date":"2025-04-11","current":41.268572,"twenty":37.537078,"median":40.501145,"eighty":44.559412,"marketCap":7807889929},{"date":"2025-04-17","current":44.145605,"twenty":37.540692,"median":40.519212,"eighty":44.559412,"marketCap":8352216066},{"date":"2025-04-25","current":43.782817,"twenty":37.571542,"median":40.572736,"eighty":44.653759,"marketCap":8377141546},{"date":"2025-05-02","current":45.953462,"twenty":37.571542,"median":40.583839,"eighty":44.677947,"marketCap":8792459672},{"date":"2025-05-09","current":43.031008,"twenty":37.571542,"median":40.598117,"eighty":44.677947,"marketCap":8233294969},{"date":"2025-05-16","current":42.422675,"twenty":37.571542,"median":40.624906,"eighty":44.677947,"marketCap":8116900028},{"date":"2025-05-23","current":42.755537,"twenty":37.571542,"median":40.666871,"eighty":44.677947,"marketCap":8180587826},{"date":"2025-05-30","current":42.698147,"twenty":37.571542,"median":40.666871,"eighty":44.677947,"marketCap":8169607171},{"date":"2025-06-06","current":42.411197,"twenty":37.571542,"median":40.666871,"eighty":44.666838,"marketCap":8114703897},{"date":"2025-06-13","current":42.927706,"twenty":37.571542,"median":40.666871,"eighty":44.666838,"marketCap":8213529790},{"date":"2025-06-20","current":43.220395,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":8269531129},{"date":"2025-06-27","current":41.894687,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":8015878004},{"date":"2025-07-03","current":41.30357,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7902777259},{"date":"2025-07-11","current":40.735409,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7794068777},{"date":"2025-07-18","current":41.234702,"twenty":37.563829,"median":40.663552,"eighty":44.606841,"marketCap":7889600473},{"date":"2025-07-25","current":42.319373,"twenty":37.604201,"median":40.725789,"eighty":44.606841,"marketCap":8097134849},{"date":"2025-08-01","current":42.372392,"twenty":37.604201,"median":40.742491,"eighty":44.606841,"marketCap":7873129491},{"date":"2025-08-08","current":43.918584,"twenty":37.604201,"median":40.752858,"eighty":44.633348,"marketCap":8160424292},{"date":"2025-08-15","current":42.901923,"twenty":37.604201,"median":40.790693,"eighty":44.633348,"marketCap":7971520467},{"date":"2025-08-22","current":44.019656,"twenty":37.604201,"median":40.820493,"eighty":44.633348,"marketCap":8179204204},{"date":"2025-08-29","current":43.199192,"twenty":37.604201,"median":40.894276,"eighty":44.633348,"marketCap":8026755504},{"date":"2025-09-05","current":42.806797,"twenty":37.595885,"median":40.935905,"eighty":44.639951,"marketCap":7953845256},{"date":"2025-09-12","current":43.841294,"twenty":37.604201,"median":40.969944,"eighty":44.633348,"marketCap":8146063183},{"date":"2025-09-19","current":42.527363,"twenty":37.604201,"median":41.008406,"eighty":44.633348,"marketCap":7901924321},{"date":"2025-09-26","current":41.962551,"twenty":37.639342,"median":41.035693,"eighty":44.633348,"marketCap":7796977752},{"date":"2025-10-03","current":42.027951,"twenty":37.639342,"median":41.102705,"eighty":44.633348,"marketCap":7809129460},{"date":"2025-10-10","current":41.974442,"twenty":37.639342,"median":41.115788,"eighty":44.633348,"marketCap":7799187153},{"date":"2025-10-17","current":44.322871,"twenty":37.639342,"median":41.17126,"eighty":44.633348,"marketCap":8235543942},{"date":"2025-10-24","current":44.544295,"twenty":37.639342,"median":41.220151,"eighty":44.656944,"marketCap":8621592904},{"date":"2025-10-31","current":43.1986,"twenty":37.639342,"median":41.2516,"eighty":44.656944,"marketCap":8361132219},{"date":"2025-11-07","current":42.991114,"twenty":37.639342,"median":41.30357,"eighty":44.656944,"marketCap":8320973082},{"date":"2025-11-14","current":43.690638,"twenty":37.639342,"median":41.35326,"eighty":44.656944,"marketCap":8456366743},{"date":"2025-11-21","current":43.68471,"twenty":37.639342,"median":41.452784,"eighty":44.656944,"marketCap":8455219339},{"date":"2025-11-28","current":44.591721,"twenty":37.639342,"median":41.521652,"eighty":44.656944,"marketCap":8630772135},{"date":"2025-12-05","current":44.093754,"twenty":37.639342,"median":41.583569,"eighty":44.656944,"marketCap":8534390208},{"date":"2025-12-12","current":42.244164,"twenty":37.639342,"median":41.619337,"eighty":44.656944,"marketCap":8176400191}],"updateTime":1765683575034},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2590552722","title":"【券商聚焦】交銀國際上調康寧傑瑞製藥(09966)評級至買入 看好其ADC產品矩陣的巨大全球市場潛力","url":"https://stock-news.laohu8.com/highlight/detail?id=2590552722","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590552722?lang=zh_tw&edition=fundamental","pubTime":"2025-12-11 09:06","pubTimestamp":1765415190,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，康宁杰瑞制药 HER2双抗ADC管线加速推进，糖基定点偶联平台持续验证：JSKN003正在进行/即将启动多项注册临床，包括2L HER2+ BC、≥2L HER2低表达BC、PROC和HER2+ CRC。JSKN016单药在TNBC中显示出优异疗效，并正在一项针对晚期NSCLC的Ib期研究中探索与卡铂、伏美替尼、及依沃西单抗等药物的联用方案，预计相关数据将于2026年公布。该机构看好公司ADC产品矩阵的巨大全球市场潜力，上调2025-27年收入预测3-8%、上调DCF目标价至13.0港元、上调评级至买入。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971330","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","ADC"],"gpt_icon":0},{"id":"2590394122","title":"新股前瞻|佈局TCE腫瘤療法千億藍海，時邁藥業能否博得市場青睞？","url":"https://stock-news.laohu8.com/highlight/detail?id=2590394122","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590394122?lang=zh_tw&edition=fundamental","pubTime":"2025-12-09 13:05","pubTimestamp":1765256702,"startTime":"0","endTime":"0","summary":"近日，又一创新药企正式向港交所提交上市申请。在此背景下，作为一家专注于实体瘤TCE疗法、且具备多款全球前列临床管线的企业，时迈药业的上市进程亦自然备受瞩目。布局TCE疗法 四款创新药物处于临床阶段智通财经APP了解到，时迈药业目前仍处于临床研发阶段，并无产品商业化。根据时迈药业招股书披露，当前仅有两款用于实体瘤的TCE药物获得全球批准，市场存在大量空白，这为具备相关布局能力的创新药企提供了结构性机遇。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4006","BK4187","IE0031619046.USD","IE00B7SZL793.SGD","LU0053666078.USD","BK4231","IE00B19Z4B17.USD","L","ADC","LU0210528500.USD","BK4107","BK4080","CRS","LU2487616109.SGD","LU0963586101.USD","LU2065731478.USD","BK4588","BK4585","ORR","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2589813345","title":"牽手尋合作，科倫博泰能否破解業績困局？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589813345","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589813345?lang=zh_tw&edition=fundamental","pubTime":"2025-12-05 22:26","pubTimestamp":1764944786,"startTime":"0","endTime":"0","summary":"12月4日，科伦药业发布公告，控股子公司科伦博泰与CrescentBiopharma建立战略合作伙伴关系，共同开发和商业化肿瘤治疗手段。高达12.5亿美元的里程碑付款预期、覆盖全球主要市场的分工布局，让这场合作披上“高光外衣”。在创新药研发风险高企的背景下，叠加科伦药业自身的业绩承压与科伦博泰的盈利下滑，这场合作引发了市场的广泛关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512053584132970.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512053584132970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4231","BK4080"],"gpt_icon":0},{"id":"2589897400","title":"超13億美元！科倫博泰 ADC 出海選擇管線互換模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2589897400","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589897400?lang=zh_tw&edition=fundamental","pubTime":"2025-12-05 20:59","pubTimestamp":1764939587,"startTime":"0","endTime":"0","summary":"12月4日，科伦博泰与Crescent共同宣布，双方已建立战略合作伙伴关系，共同开发和商业化肿瘤治疗手段（含新型联用疗法）。此次合作涉及科伦博泰的ADC产品SKB105，以及Crescent的PD-1xVEGF双特异性抗体CR-001。这两款候选药物正在开发用于治疗实体瘤，预计于2026年第一季度开展I/Ⅱ期单药治疗临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512053584080219.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512053584080219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4080","BK4231"],"gpt_icon":0},{"id":"2589289437","title":"ADC藥物與PD-1/VEGF雙抗聯用再添案例 科倫博泰與Crescent達成雙向授權協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2589289437","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589289437?lang=zh_tw&edition=fundamental","pubTime":"2025-12-05 19:52","pubTimestamp":1764935561,"startTime":"0","endTime":"0","summary":"12月4日，科伦博泰（HK06990）与CrescentBiopharma,Inc.（一家纳斯达克上市公司，以下简称Crescent）共同宣布，双方已建立战略合作伙伴关系。科伦博泰方面将ADC药物（抗体偶联药物）SKB105在中国以外权利授权Crescent，并预计将获得最高超13亿美元的授权收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512053584015760.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512053584015760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4080","LU1169590202.USD","PD","BK4023","BK4231","LU1169589451.USD"],"gpt_icon":0},{"id":"2589448869","title":"港股異動 | 百奧賽圖-B(02315)漲超3% 授權IDEAYA雙抗ADC項目IDE034獲FDA IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589448869","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589448869?lang=zh_tw&edition=fundamental","pubTime":"2025-12-05 14:46","pubTimestamp":1764917191,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B涨超3%，截至发稿，涨2.84%，报31.86港元，成交1299.1万港元。IDEAYA预计将在2026年第一季度开始患者入组，初步评估B7H3和PTK7共表达的实体瘤类型，包括肺癌、结直肠癌、头颈癌及卵巢/妇科肿瘤。此外，IDEAYA计划探索IDE034与其PARG抑制剂IDE161的联合治疗策略，以增强疗效持续性，并计划在2026年上半年重要医学会议上分享更多支持PARG与TOP1 ADC联合治疗机制的数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK1161","02315","688796","IND","BK4231","ADC"],"gpt_icon":0},{"id":"2589865213","title":"ADC與PD-1紅海之外，寶濟藥業如何找到生物醫藥的「第二增長曲線」？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589865213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589865213?lang=zh_tw&edition=fundamental","pubTime":"2025-12-05 13:33","pubTimestamp":1764912788,"startTime":"0","endTime":"0","summary":"而在ADC、PD-1等热门靶点赛道数百家企业拥挤厮杀，从临床入组速度到未来的市场定价无不白热化的竞争中，上海宝济药业股份有限公司选择了一条截然不同的差异化战略路径。与传统疗法相比，KJ103的革命性优势则在于其“快”。目前，其领先地位和临床价值已获得监管机构的高度认可。对于KJ017而言，其市场空间并不取决于自身的销量，而是与整个千亿级生物药市场的增长深度绑定，其商业模式堪称典型的“卖水人”逻辑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","161726","LU1169590202.USD","02659","BK4231","399441","ADC","LU1169589451.USD","BK4023","PD"],"gpt_icon":1},{"id":"1119124553","title":"新聞稿：Akari Therapeutics 提供公司更新，重點介紹其 ADC 載荷創新，預計將在新 CEO 角落中驅動價值","url":"https://stock-news.laohu8.com/highlight/detail?id=1119124553","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119124553?lang=zh_tw&edition=fundamental","pubTime":"2025-12-04 22:03","pubTimestamp":1764856995,"startTime":"0","endTime":"0","summary":"佛罗里达州坦帕和伦敦，2025年12月04日—— Akari Therapeutics, Plc，一家开发新型抗体药物结合物载荷的肿瘤生物科技公司，今天宣布发布了新的 CEO 角落节目，现已在公司网站上提供。在这一节目中，Akari 首席执行官 Abizer Gaslightwala 提供了公司更新，重点介绍了公司的最新进展、主要成长机会及时间表，以及这对公司未来发展的意义。利用其创新的 ADC 载荷平台，Akari 正在推进一种基于新型 PH1 载荷的新类免疫肿瘤 ADC。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4231","AKTX","ADC","BK4139","BK4080","BK4007"],"gpt_icon":0},{"id":"2588709367","title":"復宏漢霖PD-L1 ADC II期結果讀出；*ST蘇吳進入退市整理期｜醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2588709367","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588709367?lang=zh_tw&edition=fundamental","pubTime":"2025-12-02 07:01","pubTimestamp":1764630081,"startTime":"0","endTime":"0","summary":"丨2025年12月2日星期二丨NO.1复宏汉霖PD-L1ADCII期结果读出11月26日，复宏汉霖发布公告表示将在ESMOAsia2025大会上公布多项药物的临床数据。亮点之一在于核心资产PD-L1ADC药物HLX43在宫颈癌领域的II期研究结果。点评：针对PD-L1ADC开发在研管线并不多，目前进度最快的是辉瑞的PF-08046054，已至临床III期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512023579600777.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023579600777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0060","600200","PD","BK4080","BK0012","BK0239","BK0188","BK4231","159938","BK0028","BK1515","BK1574","09939","BK1161","LU1169590202.USD","02696","LU1169589451.USD","BK4023","HK0000165453.HKD","ADC"],"gpt_icon":0},{"id":"2588059978","title":"Macrogenics, Inc.盤中異動 股價大跌5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588059978","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588059978?lang=zh_tw&edition=fundamental","pubTime":"2025-12-02 01:23","pubTimestamp":1764609792,"startTime":"0","endTime":"0","summary":"北京时间2025年12月02日01时23分，Macrogenics, Inc.股票出现波动，股价急速跳水5.23%。Macrogenics, Inc.股票所在的生物技术行业中，整体跌幅为1.61%。其相关个股中，Q32 Bio Inc.、Kala Bio, Inc.、Propanc Biopharma, Inc.涨幅较大，Kala Bio, Inc.、Q32 Bio Inc.、Aditxt, Inc.较为活跃，换手率分别为1514.85%、1236.31%、132.03%，振幅较大的相关个股有Pasithea Therapeutics Corp C/Wts 12/08/2026 、Q32 Bio Inc.、Kala Bio, Inc.，振幅分别为121.69%、100.45%、72.55%。Macrogenics, Inc.公司简介：Macrogenics Inc是一家生物技术公司，专注于发现和开发用于治疗癌症的基于抗体的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202012312952511d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202012312952511d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4080","MGNX","BK4231","BK4139","ADC"],"gpt_icon":0},{"id":"2586389271","title":"興證國際：首予映恩生物-B(09606)「增持」評級 公司立足創新持續引領下一代ADC研發浪潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2586389271","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586389271?lang=zh_tw&edition=fundamental","pubTime":"2025-11-28 09:08","pubTimestamp":1764292136,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，兴证国际发布研报称，首次覆盖，给予映恩生物-B“增持”评级，映恩生物聚焦 ADC 赛道领域，借助与 BioNTech 等全球领先药企的合作，以中国速度推进全球多中心临床快速布局，在 ADC 领域占据有利的竞争身位。兴证国际主要观点如下：近期事件2025 年 10 月 23 日公司举办研发日，介绍公司 ADC 产品管线近期进展以及未来发展方向。2025 年 11 月 14 日公司自身免疫 ADC 产品管线 DB-2304用于系统性红斑狼疮临床全球 1/2a期研究的 2a 期部分完成首例患者给药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","06058","09606"],"gpt_icon":0},{"id":"2586428185","title":"港股異動 | 中國生物製藥(01177)漲超4% 旗下正大晴天自研HER2雙抗ADC新輔助治療乳腺癌取得重要突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2586428185","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586428185?lang=zh_tw&edition=fundamental","pubTime":"2025-11-26 10:28","pubTimestamp":1764124108,"startTime":"0","endTime":"0","summary":"消息面上，11月25日，注射用TQB2102单药用于HER2阳性乳腺癌新辅助治疗的Ⅱ期临床研究结果，获国际著名期刊《临床肿瘤学杂志》 在线发表。TQB2102是中国生物制药旗下正大天晴自主研发的一种靶向HER2两个非重叠表位ECD2及ECD4的抗体偶联药物。该项研究由复旦大学附属肿瘤医院邵志敏教授团队领衔，为首个证实双表位HER2 ADC TQB2102在乳腺癌新辅助治疗阶段具有良好疗效和安全性的研究，Ⅲ期注册临床研究正在开展中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","HK0000165453.HKD","IE00BZ08YT58.USD","BK1521","IE00BZ08YR35.GBP","BK4080","BK4231","BK1515","IE00BZ08YS42.EUR","01177","BK1191","ADC"],"gpt_icon":0},{"id":"2586474498","title":"科倫博泰 ADC 聯合 K 藥闖過一線肺癌 III 期，中國患者將迎新方案？","url":"https://stock-news.laohu8.com/highlight/detail?id=2586474498","media":"制药在线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586474498?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 11:40","pubTimestamp":1764042014,"startTime":"0","endTime":"0","summary":"摘要：11 月 24 日，默沙东合作伙伴科伦博泰宣布，其 TROP2 靶向 ADC 药物 sacituzumab tirumotecan联合 Keytruda，在一线 PD-L1 阳性非小细胞肺癌III 期试验中获胜。这也是全球首 个 ADC 与免疫检查点抑制剂组合，在一线 NSCLC III 期试验中达成主要终点，但试验设计局限使其对欧美市场参考价值有限。科伦博泰透露，sac-TMT 目前有 10 项肺癌注册研究在推进，其中 5 项是默沙东主导的全球 III 期，但这些试验结果尚未公布。眼下，科伦博泰已启动中国上市申请的准备工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125114026a4b874ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125114026a4b874ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B1BXHZ80.USD","LU0265550946.USD","LU2089984988.USD","LU1037948541.HKD","LU0234572021.USD","LU2106854487.HKD","LU0985320562.USD","BK4231","SG9999001176.USD","LU1162221912.USD","IE00BSNM7G36.USD","LU2461242641.AUD","MRK","SG9999014575.USD","LU0106261372.USD","LU0266013472.USD","IE00BLSP4239.USD","BK4585","SG9999014567.USD","LU1116320901.HKD","IE00BN8TJ469.HKD","IE000M9KFDE8.USD","SG9999015358.SGD","ADC","BK4550","LU0320765489.SGD","III","LU1066051498.USD","LU0203345920.USD","SGXZ57979304.SGD","LU2361044949.HKD","BK4559","LU1989772923.USD","SG9999002232.USD","BK4080","LU1037948897.HKD","BK4516","LU0203347892.USD","LU2023250504.SGD","LU0070302665.USD","LU1291159041.SGD","SG9999015341.SGD","LU1035773651.USD","LU0058720904.USD","LU1057294990.SGD","LU0965509101.SGD","LU0965509283.SGD","LU1989772840.SGD","LU0238689110.USD","LU0861579265.USD"],"gpt_icon":0},{"id":"2586341050","title":"港股異動 | 和鉑醫藥-B(02142)漲近5% 與阿斯利康進一步拓展合作範圍 開發ADC及T細胞銜接器療法","url":"https://stock-news.laohu8.com/highlight/detail?id=2586341050","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586341050?lang=zh_tw&edition=fundamental","pubTime":"2025-11-25 10:23","pubTimestamp":1764037381,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B(02142)涨近5%，截至发稿，涨4.92%，报13.62港元，成交额1542.11万港元。消息面上，11月24日，和铂医药-B发布公告，有关公司的间接全资附属公司和铂医药(上海)有限责任公司(和铂上海)与AstraZeneca PLC (AstraZeneca)订立合作、选择权及许可协议，于2025年11月24日，经修订和铂上海与 AstraZeneca订立的合作协议后，订约双方的合作范围进一步扩展，旨在结合两家公司的专业知识，共同发现及开发包括抗体偶联药物(ADC)及T细胞衔接器在内的新一代生物疗法。经济条款与合作协议项下建立的财务框架仍然一致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320765992.SGD","02142","LU0109394709.USD","LU2456880835.USD","BK4080","BK1583","BK1161","BK4585","LU2462157665.USD","LU1829250122.USD","ADC","BK4568","BK4007","LU0889565916.HKD","LU2236285917.USD","AZN","BK4231","BK4588","BK1574","LU2417539215.USD"],"gpt_icon":0},{"id":"2585631430","title":"和鉑醫藥-B與 AstraZeneca修訂合作協議 合作範圍進一步擴展","url":"https://stock-news.laohu8.com/highlight/detail?id=2585631430","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585631430?lang=zh_tw&edition=fundamental","pubTime":"2025-11-24 08:05","pubTimestamp":1763942700,"startTime":"0","endTime":"0","summary":"和铂医药-B(02142)公布，有关公司的间接全资附属公司和铂医药(上海)有限责任...和铂医药-B(02142)公布，有关公司的间接全资附属公司和铂医药(上海)有限责任公司(和铂上海)与AstraZeneca PLC (AstraZeneca)订立合作、选择权及许可协议，于2025年11月24日，经修订和铂上海与 AstraZeneca订立的合作协议后，订约双方的合作范围进一步扩展，旨在结合两家公司的专业知识，共同发现及开发包括抗体偶联药物(ADC)及T细胞衔接器在内的新一代生物疗法。经济条款与合作协议项下建立的财务框架仍然一致。追加内容本文作者可以追加内容哦 !","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124080807977b515f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124080807977b515f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU1829250122.USD","LU2236285917.USD","BK4231","BK4080","LU2456880835.USD","LU2462157665.USD","BK4568","AZN","BK4585","LU0320765992.SGD","LU2417539215.USD","BK4007","BK4588","LU0889565916.HKD","ADC"],"gpt_icon":0},{"id":"2585111739","title":"百利天恆：全球首個EGFR x HER3雙抗ADC藥物iza-bren上市申請成功獲CDE受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2585111739","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585111739?lang=zh_tw&edition=fundamental","pubTime":"2025-11-21 18:15","pubTimestamp":1763720112,"startTime":"0","endTime":"0","summary":"人民财讯11月21日电，2025年11月21日，国家药品监督管理局药品审评中心（CDE）官网显示，由百利天恒自主研发、全球首创（First-in-class）、新概念（Newconcept）且唯一进入III期临床阶段EGFRxHER3双抗ADC药物iza-bren的上市许可申请，成功获得国家药监局受理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511213571533576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","LU1223082519.USD","LU1223083913.SGD","ADC","BK4017","91194","CDE","LU1223082196.USD","02615","BK4231","BK0239","BK4080"],"gpt_icon":0},{"id":"2584135516","title":"智通港股解盤 | 券商收購合併再起 傳聞引發地產走強","url":"https://stock-news.laohu8.com/highlight/detail?id=2584135516","media":"智通财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584135516?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 19:27","pubTimestamp":1763638024,"startTime":"0","endTime":"0","summary":"隔夜，美联储发布10月议息会议纪要。纪要显示，在这次最终决定降息的会议上，美联储委员\"分歧严重\"。关键时刻出现利好传闻，知情人士称中国正考虑采取新措施，来扭转房地产市场低迷情势。不过这只是传闻，并未获得证实。此外，有行业厂商目前仍分批对不同覆铜板产品价格进行调整。2025H1，公司总收入74.34亿元，同比增长14.3%；归母净利润为31.35亿元，同比增长15.02%。阿美替尼作为国产首款三代EGFRTKI，销售增长迅速，适应症持续拓展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","LU2236285917.USD","NVDD","IE0004086264.USD","NVDY","01109","NVIW.SI","82331","02331","03896","ADC","SG9999002232.USD","01658","01635","NVDS.UK","LU1328615791.USD","LU2111349929.HKD","01359","01729","00688","NVD","LU0786609619.USD","NVDS","SNVD.UK","02577","03121","01888","NVD3.UK","3NVD.UK","02631","03143","01918","03692","LU1989772923.USD","03988","BK4587","NVDU","2NVD.UK","00148","00914","NVD2.UK","01988","02423","NVDX","LNNGY","01880","03323"],"gpt_icon":1},{"id":"2584979211","title":"開發下一代 ADC，新鋭孖展1.2億美元，默沙東支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2584979211","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584979211?lang=zh_tw&edition=fundamental","pubTime":"2025-11-19 22:12","pubTimestamp":1763561520,"startTime":"0","endTime":"0","summary":"Solve Therapeutics，一家开发实体瘤ADC药物的生物技术公司，宣布完成1.2亿美元超额认购融资，此轮融资由Yosemite领投，Alexandria Venture Investments、默沙东等多家机构参投，未提及财务顾问。该公司由行业资深领导者于2021年创立，已累计融资3.21亿美元。其核心技术CloakLink旨在增强ADC药物血浆稳定性，改善药代动力学，降低毒性。主要项目SLV-154和SLV-324正在进行I期临床试验，配备新诊断方法以实现精确患者选择。最新融资将用于加速临床管线和专有CloakLink连接子平台开发，支持两个项目的Ib期研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120014629a4ad5af9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251120014629a4ad5af9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0070302665.USD","SG9999014567.USD","SG9999014542.SGD","LU1929549753.HKD","LU0211331839.USD","LU0320765489.SGD","MRK","BK4533","IE00B2B36J28.USD","LU2112291526.USD","SG9999002224.SGD","LU2023250843.SGD","LU0208291251.USD","BK4588","LU0203345920.USD","SG9999002232.USD","LU1066051225.USD","IE0009355771.USD","LU1585245621.USD","IE00BFTCPJ56.SGD","LU1941712348.USD","LU2361044949.HKD","SGXZ57979304.SGD","BK4550","LU2361044865.SGD","IE00BLSP4452.SGD","LU0320765646.SGD","LU1989771016.USD","LU1035773651.USD","LU2361045086.USD","LU0861579265.USD","LU0098860793.USD","LU1023059063.AUD","LU1974910355.USD","IE000M9KFDE8.USD","LU0265550946.USD","LU0266013472.USD","LU1934455863.HKD","LU1069347547.HKD","LU0234572021.USD","SG9999015341.SGD","LU1917777945.USD","BK4559","LU1699723380.USD","BK4534","ADC","LU1430594728.SGD","LU0058720904.USD","SG9999015358.SGD","LU1066051811.HKD"],"gpt_icon":0},{"id":"2584938632","title":"中國生物製藥(01177)：LM-350「CDH17 ADC」臨牀試驗申請獲NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2584938632","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584938632?lang=zh_tw&edition=fundamental","pubTime":"2025-11-18 17:36","pubTimestamp":1763458582,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团全资附属公司礼新医药科技(上海)有限公司自主研发的国家1类创新药LM-350“CDH17抗体偶联药物”已获得中国国家药品监督管理局的临床试验批准。LM-350是基于礼新医药新一代LM-ADC平台开发的一款靶向CDH17的ADC，能够高度选择性地结合CDH17，具有很强的内化能力。LM-350采用IgG1野生型构型，同时具备抗体依赖细胞介导的细胞毒性作用活性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","IE00BZ08YR35.GBP","BK4080","BK1521","HK0000165453.HKD","BK1589","BK1515","BK1191","BK4231","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","01177"],"gpt_icon":0},{"id":"2584981992","title":"歷史性突破！「中國智造」ADC新藥全球首個取得食管癌III期臨牀研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2584981992","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584981992?lang=zh_tw&edition=fundamental","pubTime":"2025-11-18 15:37","pubTimestamp":1763451420,"startTime":"0","endTime":"0","summary":"2025年11月17日，由科创板头部企业百利天恒自主研发的全球首创、新概念双特异性抗体偶联药物药物iza-bren，在针对晚期食管鳞癌的III期临床试验达到无进展生存期和总生存期双主要终点。这是全球首个由ADC药物在食管癌治疗中取得双阳性结果的III期临床研究。　　在中国，每年有超过22万人被诊断患上食管癌，占到全球每年新发食管癌患者的一半左右，是食管癌患病人数和死亡人数最多的国家。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-11-18/doc-infxviex4517981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4080","ADC","BK4134","BK4231","III"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":192,"code":"91000000","status":"200"}]}}